Stock RAYT RAYONT INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Rayont Inc.

Equities

RAYT

US75508M1009

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 08:39:38 30/04/2024 pm IST 		5-day change 1st Jan Change
0.1 USD +19,900.00% Intraday chart for Rayont Inc. -.--% -.--%
2023 Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
2023 Rayont Inc. Announces Board Appointments CI

Valuation

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Capitalization 1 0.7546 1.415 14.95 0.9035 139.4 45.69
Enterprise Value (EV) 1 0.7903 1.636 15.14 1.044 141.8 53.47
P/E ratio -1.96 x -7.62 x -1.75 x -3.97 x 293 x 186 x
Yield - - - - - -
Capitalization / Revenue 1.15 x 61.4 x - 4.84 x 46.9 x 16.1 x
EV / Revenue 1.2 x 71 x - 5.6 x 47.8 x 18.8 x
EV / EBITDA -2.09 x -11.2 x -13.1 x -7.61 x -685 x -53.4 x
EV / FCF 1.96 x -18 x 176 x 0.6 x - -9.12 x
FCF Yield 51.1% -5.57% 0.57% 167% - -11%
Price to Book -21.2 x -6.4 x 3.27 x 2.95 x 30.2 x 8.97 x
Nbr of stocks (in thousands) 1,887 1,887 59,800 12,908 46,778 48,095
Reference price 2 0.4000 0.7500 0.2500 0.0700 2.980 0.9500
Announcement Date 29/12/17 11/12/18 17/03/20 18/12/20 29/12/22 29/12/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Net sales 1 0.6578 0.023 - 0.1867 2.97 2.839
EBITDA 1 -0.3786 -0.1454 -1.155 -0.1373 -0.207 -1
EBIT 1 -0.384 -0.1465 -1.26 -0.2389 -0.6615 -1.486
Operating Margin -58.37% -635.67% - -127.96% -22.28% -52.35%
Earnings before Tax (EBT) 1 -0.3851 -0.1856 -1.263 -0.2294 0.3839 0.2691
Net income 1 -0.3851 -0.1856 -1.263 -0.2294 0.3839 0.2449
Net margin -58.54% -805.36% - -122.92% 12.93% 8.62%
EPS 2 -0.2041 -0.0984 -0.1425 -0.0176 0.0102 0.005112
Free Cash Flow 1 0.4038 -0.0911 0.0861 1.749 - -5.864
FCF margin 61.39% -395.3% - 936.73% - -206.54%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 29/12/17 11/12/18 17/03/20 18/12/20 29/12/22 29/12/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2017 2018 2019 2020 2021 2022
Net Debt 1 0.04 0.22 0.19 0.14 2.4 7.78
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -0.0942 x -1.518 x -0.1639 x -1.027 x -11.61 x -7.776 x
Free Cash Flow 1 0.4 -0.09 0.09 1.75 - -5.86
ROE (net income / shareholders' equity) -126% 145% -330% -24% - 5.55%
ROA (Net income/ Total Assets) -51.8% -322% -132% -6.71% - -8.7%
Assets 1 0.7439 0.0577 0.9594 3.419 - -2.814
Book Value Per Share 2 -0.0200 -0.1200 0.0800 0.0200 0.1000 0.1100
Cash Flow per Share 2 0.0300 0 0 0 0.0100 0
Capex - 0.01 - - 1.72 3.19
Capex / Sales - 32.01% - - 57.94% 112.4%
Announcement Date 29/12/17 11/12/18 17/03/20 18/12/20 29/12/22 29/12/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
RAYONT INC. Stock Rayont Inc.
-.--% 4.57M
MODERNA, INC. Stock Moderna, Inc.
+33.63% 50.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.82B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.03B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.11B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 19.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.05B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.08B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RAYT Stock
  4. Financials Rayont Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW